ArticleJournal of translational medicine2026
HIF-1α attenuates ferroptosis-associated dermal fibroblast senescence via modulation of NF-κB-DPP4 signaling.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanocarrier-mediated targeting of chemotherapy-induced DPP4 enhances T cell infiltration and improves cancer immunochemotherapy.Bioactive materials · 2027Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundsSkin aging is characterized by progressive structural and functional decline driven in part by chronic oxidative stress. Ferroptosis-associated processes have been increasingly implicated in cellular senescence and are linked to dipeptidyl peptidase-4 (DPP4). Although hypoxia-inducible factor-1α (HIF-1α) is essential for skin homeostasis, its role in dermal fibroblast aging remains incompletely understood. This study aimed to determine whether HIF-1α modulates ferroptosis-associated senescence in human dermal fibroblasts (HDFs) and to explore the involvement of NF-κB-DPP4 signaling.
methodsHIF-1α expression was examined in aged HDFs and sun-exposed human skin. Transcriptomic profiling was performed to assess pathways associated with hypoxia in aging models. Pharmacological modulators of ferroptosis, DPP4, and HIF-1α were applied in vitro to evaluate effects on senescence and ferroptotic markers. NF-κB activity and DPP4 transcription were analyzed using molecular assays. Potential in vivo relevance was evaluated in aged mice treated with a HIF-1α activator or a ferroptosis inhibitor.
resultsHIF-1α expression was reduced in aged HDFs and photoaged skin, and its depletion accelerated cellular senescence. Transcriptomic analysis suggested downregulation of ferroptosis-related pathways under hypoxic conditions. Induction of ferroptosis-associated stress promoted senescence phenotypes in HDFs, whereas hypoxia-induced HIF-1α activation attenuated these effects. Mechanistically, NF-κB functioned as a transcriptional regulator of DPP4, and hypoxia was associated with reduced NF-κB activity, decreased DPP4 expression, and lower secretion of soluble DPP4 (sDPP4). Inhibition of DPP4 mitigated ferroptosis-associated senescence and restrained sDPP4-mediated paracrine propagation to neighboring young fibroblasts. In aged mice, topical treatment with a HIF-1α activator or a ferroptosis inhibitor was associated with improved dermal structure and reduced senescence markers.
conclusionThese findings support a model in which HIF-1α is associated with suppression of NF-κB-dependent DPP4 expression and attenuation of ferroptosis-associated fibroblast senescence. Targeting the HIF-1α/NF-κB/DPP4 axis may represent a potential strategy for mitigating skin aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.